CER Daily Newsfeed

The RWE Communication Gap That's Costing Manufacturers Formulary Access

(7/2, Stephen Appezzato, Pharmaceutical Commerce) reports “...Payers say they want real-world evidence to inform formulary positioning, set utilization management criteria, and underwrite the outcomes-based contracts that tie reimbursement to what a therapy actually delivers outside the clinic. Health care professionals want it to target the right therapies to the right patients without cycling through trial and error. Used well, it is a powerful commercial tool manufacturers have for improving access, commercial success, and patient benefit. The problem, and the fix, is in how that evidence gets communicated.” Full

Produodopa's Positive RWE for Parkinson's Disease to Boost Clinician Confidence in Crowded Levodopa Market

(7/1, PharmaLive.com) reports “...At the European Academy of Neurology (EAN) 2026 virtual congress, AbbVie presented new 12-month interim data from the ROSSINI study, supporting the real-world safety and effectiveness of Produodopa in patients with advanced Parkinson's disease. Sustained improvements were observed across motor fluctuations, non-motor symptoms, and selected quality-of-life outcomes. Positive real-world evidence (RWE) for Produodopa could boost clinician confidence in a crowded levodopa market, says GlobalData.” Full

CBD Reduces Seizures in Drug-Resistant Pediatric Epilepsy, Study Finds

(7/2, Medical Xpress) reports “...Lead researcher Dr. Daniel Perkins from the University of Melbourne said, ‘This new study provides real-world evidence showing CBD's therapeutic potential extends beyond Dravet and Lennox-Gastaut syndromes.’” Full

NHS Drug Pricing Deal With Donald Trump Will 'Cause More Deaths Than Covid'

(7/1, Martin Bagot, Mirror) reports “...A health assessment of the US trade deal showed it could lead to 229,000 deaths by 2036 if funding was diverted from other NHS care to pay for medicines. The analysis by experts at Liverpool University showed £45billion in NHS funding would need to be found by 2036 to pay US drug companies higher prices. Experts warn the deal to appease President Trump will mean less money to spend on NHS staff and equipment.” Full